Lapatinib and Cetuximab in Patients With Solid Tumors

Inclusion Criteria: * At least one measurable lesion by RECIST criteria * A tumor lesion that can be readily biopsied using a core needle via clinical exam, ultrasound, CT, or fluoroscopic-guidance * Over the age of 18 years and able to provide informed consent * Patients must have progressed after standard therapy for metastatic/ recurrent disease including 5-FU containing regimens for patients with colorectal cancer, and platinum-containing regimens for patients with head and neck cancer and non-small cell lung cancer. * Patients may have received cetuximab, panitumumab or erlotinib previously * Adequate kidney, liver, and bone marrow function * Life expectancy greater than 3 months * ECOG performance status \</= 2 * Normal left ventricular ejection fractions Exclusion Criteria: * Chemotherapy or surgery within 4 weeks prior to treatment start * Radiation treatment within 3 weeks prior to treatment start * Prior therapy with lapatinib * Untreated brain metastasis or neurologically unstable CNS metastases * Any severe or uncontrolled medical condition or other condition that could affect participation in this study including unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction \</= 6 months prior to study entry * Diarrhea \> grade 1 at baseline * Patients on a medication or herbal therapy known to inhibit CYP3A4 * Gastrointestinal tract disease resulting in the inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption or active peptic ulcer disease * Ongoing ventricular cardiac dysrhythmias of grade \>/= 2 * Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation \>= 3 beats in a row) * Serious cardiac arrhythmia requiring medication * QTc interval \> 500 msec * Female patients who are pregnant or breast feeding, or adults who are of reproductive potential and are unwilling to refrain from conceiving a child during study treatment * Patients unwilling or unable to comply with the protocol or provide informed consent